



## **PRESS RELEASE**

### **Crucell and UCB sign STAR™ License Agreement**

**Leiden, The Netherlands, September 7, 2006** - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed a STAR™ licensing agreement with UCB (Euronext: UCB), a leading biopharmaceutical company with headquarters in Brussels, making UCB the first European STAR™ licensee. The agreement covers a 5-year non-exclusive STAR™ research license for the production of monoclonal antibodies.

UCB will evaluate STAR™ technology using its proprietary mammalian CHO cell line with a variety of different human and mouse chimeric and humanized antibodies. Under the terms of the agreement, UCB will pay a license issuance fee, milestone fees and annual maintenance fees. Further financial details were not disclosed.

"As a biopharmaceutical leader, UCB is committed to continuously enhancing its drug development," commented Neil Weir, Vice President, Research, UCB. "Therefore, UCB is looking forward to evaluating the STAR™ technology in close collaboration with Crucell. This new technology could become a valuable addition to UCB's growing suite of mammalian cell expression technologies, thus potentially increasing UCB's antibody production capabilities."

"We are very pleased to announce the first European STAR™ technology licensing agreement," added Crucell's CEO Ronald Brus. "UCB have already licensed our PER.C6® technology, and the addition of a STAR™ technology licensing agreement further enhances the relationship between the two companies."

#### **About Crucell**

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B and a virosomal vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminium-free hepatitis A vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy and Korea. The Company employs about 900 people. For more information, please visit [www.crucell.com](http://www.crucell.com).

#### **About UCB**

UCB ([www.ucb-group.com](http://www.ucb-group.com)) is a leading global biopharmaceutical company dedicated to the research, development and commercialisation of innovative



pharmaceutical and biotechnology products in the fields of central nervous system disorders, allergy/respiratory diseases, immune and inflammatory disorders and oncology – UCB focuses on securing a leading position in severe disease categories. Employing over 8,300 people in 40 countries, UCB achieved revenue of 2.3 billion euro in 2005. UCB is listed on the Euronext Brussels Exchange, with worldwide headquarters located in Brussels, Belgium.

**Crucell's Licensing Program Disclosure Policy**

*Crucell believes it has a duty to inform (potential) investors and other stakeholders about every licensing agreement it reaches with third parties – regardless of the significance of current or future revenue or royalties generated by the agreement. Crucell fulfils this duty by issuing a press release that invariably consists of the name of the contract party, the nature of the license and an indication of the relevant technology or therapeutic area. This ensures that every potential investor or interested party can be fully up-to-date with all licensing agreements made by Crucell with third parties. An overview of all Crucell's licensees and partners can be found on the Company's website, including an overview of each relevant product's phase of development.*

**Forward-looking statements**

*This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled "Risk Factors". The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).*

**For further information please contact:**

**Crucell N.V.**

Paul Vermeij  
Director Investor Relations and  
Corporate Communications  
Tel. +31 (0)71 524 8718  
[p.vermeij@crucell.com](mailto:p.vermeij@crucell.com)

**For Crucell in the US:  
Redington, Inc.**

Thomas Redington  
Tel. +1 212-926-1733  
[tredington@redingtoninc.com](mailto:tredington@redingtoninc.com)